A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to

Recruiting

99 years or below

All

Phase 3

5 participants needed

1 Location

Brief description of study

The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Ulcerative Colitis
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 829968

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

Brief description of study

Eligibility of study

Find a site

Interested in the study